X8Q
[3-[2-(dimethylamino)ethyl]-1~{H}-indol-4-yl] dihydrogen phosphate
Find entries where: X8Q
is present as a standalone ligand in 1 entries
Chemical Component Summary | |
---|---|
Name | [3-[2-(dimethylamino)ethyl]-1~{H}-indol-4-yl] dihydrogen phosphate |
Identifiers | [3-[2-(dimethylamino)ethyl]-1~{H}-indol-4-yl] dihydrogen phosphate |
Formula | C12 H17 N2 O4 P |
Molecular Weight | 284.248 |
Type | NON-POLYMER |
Isomeric SMILES | CN(C)CCc1c[nH]c2c1c(ccc2)OP(=O)(O)O |
InChI | InChI=1S/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17) |
InChIKey | QVDSEJDULKLHCG-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 36 |
Chiral Atom Count | 0 |
Bond Count | 37 |
Aromatic Bond Count | 10 |
Drug Info: DrugBank
DrugBank ID | DB11664 |
---|---|
Name | Psilocybin |
Groups | investigational |
Description | Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA. |
Synonyms |
|
Categories |
|
CAS number | 520-52-5 |
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL194378 |
PubChem | 138543650, 10624 |
ChEMBL | CHEMBL194378 |
ChEBI | CHEBI:8614 |